| 周明琪,耿瑞花,方素芹,刘 莉,王 娟.长期吸入布地奈德联合孟鲁司特钠治疗过敏性哮喘基因阳性患儿的临床观察[J].现代生物医学进展英文版,2019,19(14):2716-2720. |
| 长期吸入布地奈德联合孟鲁司特钠治疗过敏性哮喘基因阳性患儿的临床观察 |
| Clinical Observation of the Effect of Long-Term Inhalation of Budesonide Combined with Monteluster Sodium on Children with Gene Positive Allergic Asthma |
| Received:May 08, 2019 Revised:May 31, 2019 |
| DOI：10.13241/j.cnki.pmb.2019.14.024 |
| 中文关键词: 过敏性哮喘基因阳性 布地奈德 孟鲁司特钠 |
| 英文关键词: Allergic asthma gene positive Budesonide Montelukast sodium |
| 基金项目:山东省医药卫生科技发展计划项目(2015WS0131) |
| Author Name | Affiliation | E-mail | | ZHOU Ming-qi | Shengli Oilfield Central Hospital, Pediatrics, Shandong, Dongying, 257034, China | liqian200801@163.com | | GENG Rui-hua | Dongying Kenli District People's Hospital, Pediatrics, Shandong, Dongying, 257500, China | | | FANG Su-qin | Dongying Kenli District People's Hospital, Pediatrics, Shandong, Dongying, 257500, China | | | LIU Li | Affiliated Hospital of Taishan Medical College, Department of Pediatrics, Shandong, Taian, 271000, China | | | WANG Juan | Affiliated Hospital of Taishan Medical College, Department of Pediatrics, Shandong, Taian, 271000, China | |
|
| Hits: 1020 |
| Download times: 725 |
| 中文摘要: |
| 摘要 目的：观察长期吸入布地奈德联合孟鲁司特钠治疗过敏性哮喘基因阳性患儿的临床疗效。方法：将88例支气管哮喘患儿按简单随机法分为对照组(n=46)和研究组(n=42)，两组均予以常规治疗，对照组在常规治疗基础上长期吸入布地奈德治疗，研究组在对照组基础上联合孟鲁斯特钠治疗，比较两组临床疗效、症状及体征消失时间，治疗前后嗜酸粒细胞阳离子蛋白(ECP)、嗜酸粒细胞(EOS)计数、免疫球蛋白(IgE)、白介素-4(IL-4)和肺功能的变化及不良反应的发生情况。结果：治疗后，研究组总有效率显著高于对照组(97.62% vs. 84.78%，P<0.05)，气促、哮鸣音、肺部啰音、咳嗽消失时间均明显短于对照组(P<0.05)。治疗前，两组ECP、EOS、IgE、IL-4水平、峰值呼气流速(PEF)、第一秒用力呼气容积(FEV1)比较差异无统计学意义(P>0.05)；治疗后，两组ECP、EOS、IgE及IL-4水平较治疗前下降(P<0.05)，研究组以上指标低于对照组(P<0.05)，两组治疗后PFE及FEV1较治疗前心脏上升，且研究组以上指标明显高于对照组(P<0.05)。两组总不良反应发生率比较差异无统计学意义(P>0.05)。结论：长期吸入布地奈德联合孟鲁斯特纳可提高过敏性哮喘基因阳性患儿的疗效，显著减轻患儿症状，控制气道炎症反应，改善肺功能。 |
| 英文摘要: |
| ABSTRACT Objective: To observe the clinical effect of long-term inhalation of budesonide combined with montelulast sodium in children with gene positive allergic asthma. Methods: 88 cases of children with bronchial asthma according to simple random method were divided into the control group (n=46) and research group (n=42), both groups of conventional treatment, the control group on the basis of routine therapy long-term inhaled budesonide therapy, the research group was treated with montelukast sodium on the basis of the control group, then clinical curative effect, the symptoms and signs disappeared time comparison, acidophilic granulocyte cationic protein (ECP), acidophilic granulocyte (EOS) counting, immunoglobulin (IgE), interleukin 4 (IL-4) and pulmonary function changes before and after the treatment, and adverse reactions occur in both group were compared. Results: After treatment, the total effective rate in the research group was higher than that in the control group, and the disappearance time of shortness of breath, wheeze, rumble in lungs and cough was lesser than that in the control group, the difference was statistically significant (P<0.05). Before treatment, levels of ECP, EOS, IgE and IL-4, PEF and FEV1 in the two groups were no significant difference (P>0.05). After treatment, the levels of ECP, EOS, IgE and IL-4 in both groups were decreased compared with that before treatment, the above indexes in the research group were lower than those in the control group, PFE and FEV1 were higher than those before treatment, and the differences in the research group were statistically significant (P<0.05). There was no statistically significant difference in the incidence of total adverse reactions between the two groups (P>0.05). Conclusion: long-term inhalation of budesonide combined with monrostner can improve the efficacy of children with allergic asthma gene positive, reduce symptoms, control airway inflammation and improve lung function. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
